Stockholm, Sweden

Hans-Peter Ekre

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.8

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Hans-Peter Ekre

Introduction

Hans-Peter Ekre is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of medical science, particularly in the development of chemically modified heparins. With a total of 3 patents, his work has the potential to impact treatments for various diseases.

Latest Patents

One of his latest patents is focused on low anticoagulant heparins. This invention relates to a chemically modified heparin, which has an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg, and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. The patent also discloses a method for preparing this heparin and its medical use, including treatment for malaria. Another significant patent involves the use of chemically modified heparin derivatives in treating sickle cell disease, again with specific activity and molecular weight parameters.

Career Highlights

Throughout his career, Hans-Peter Ekre has worked with various companies, including Dilaforette AB and Dilafor AB. His innovative work in the field of heparin modification has positioned him as a key figure in medical research.

Collaborations

He has collaborated with notable individuals in the field, including Ulf Lindahl and Erik Yngve Holmer. These collaborations have likely contributed to the advancement of his research and inventions.

Conclusion

Hans-Peter Ekre's contributions to the field of medical science through his patents on chemically modified heparins demonstrate his innovative spirit and dedication to improving healthcare. His work continues to pave the way for new treatments and advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…